Future health of parents and children affected by endocrine and liver disorders in pregnancy
Why it is important
The children of women with ICP, HG, GDM, T1DM, and T2DM are at an increased risk of adiposity, dyslipidaemia, insulin resistance, and hepatic steatosis in later life. These conditions are clinically significant because they place children at risk of adult obesity, metabolic disease, diabetes, hypertension, and fatty liver, which can progress to cirrhosis. These conditions may reduce the overall health and quality of life of affected individuals. Alongside the risks for children of women with metabolic disorders, childhood obesity is increasing across the population. Therefore, it is crucial to find therapies that can improve the health of these high-risk children and young people.
Summary of current research
We have evaluated the impact of drug treatments during pregnancy for ICP and GDM on the future health of fetuses exposed to these conditions using in vivo models. Some drugs can improve the future health of offspring from pregnancies affected by metabolic disorders. Ongoing research is investigating the impact of drug treatments during pregnancy on babies exposed to UDCA. Additionally, we are studying intermittent cold exposure (ICE) on metabolic health, specifically whether ICE, delivered through a cooling garment or equivalent, can enhance the function of brown adipose tissue and, in turn, improve the metabolic health of babies, children, and young people. In vivo studies are investigating the mechanisms by which ICE can improve metabolic health.
How the research benefits patients
Safe, pregnancy-compatible treatments or novel, comfortable devices:
- Collaboration with patients to assess these options.
- Aim: Improve the long-term health of children and young people at risk of adiposity-related disorders.
Researchers
- Alice Mitchell
- Madeleine Reid
- Josca Mariette Schoonejans